

30 October 2026

The General Manager
Pakistan Stock Exchange Limited
Stock Exchange Building,
Stock Exchange Road,
Karachi.

Subject: Disclosure of Material Information

Dear Sir / Madam,

In accordance with Sections 96 and 131 of the Securities Act, 2015 and Clause 5.6.1(a) of the Rule Book of the Pakistan Stock Exchange Limited, we hereby convey the following:

Haleon Pakistan Limited is pleased to announce that it has commenced manufacturing of Panadol 500mg tablets at its own manufacturing facility located in Jamshoro, Pakistan.

The commencement of inhouse manufacturing follows the Company's previously announced investment on [13 October 2023](#) in its Jamshoro facility to produce the Panadol base portfolio. This investment was undertaken to bring the latest manufacturing technology to Pakistan and to enhance the Company's production capacity.

As a part of the transition to inhouse manufacturing, Panadol 500mg tablets manufactured at the Jamshoro facility will also feature a **new tablet design, with a beacon engraving replacing the existing "Panadol" text engraving**. This change relates to the tablet design only, with the quality and efficacy of the product remaining unchanged.

The commencement of manufacturing of Panadol 500mg tablets at the Company's Jamshoro facility represents a significant milestone for Haleon Pakistan Limited as a major step forward in strengthening its inhouse manufacturing capabilities, and bolstering the reliable availability of its products for consumers in Pakistan.

Yours sincerely,
For and on behalf of Haleon Pakistan Limited

Mr. Qawi Naseer
Chief Executive Officer and General Manager

CC: Executive Director / HOD,
Offsite-II Department, Supervision Division,
Securities and Exchange Commission of Pakistan,
NIC Building, 63 Jinnah Avenue,
Blue Area, Islamabad.